• Vision:

Improving patients life after severe neurological diseases

Building the future of Neuroscience

• Mission

Platform

Shaping the Future of Targeted Treatment

We develop universally applicable technologies that deliver therapeutics directly to the affected organs – exactly where they are most urgently needed.

Highly effective Minimal invasive Less side effects

• Platform

First Application

Targeted treatment platform

Targeted Cure Tec has developped a novel medical drug device concept

Our novel medical device technology

Device:
Endovascular drug delivery system
Formulation:
Slow release drug formulation
Platform analytics:
A platform technology having multiple applications (formulation & indication) powered by prediction models

• First Application

Competence

Aneurysmal subarachnoid hemorrhage: Unmet need to improve patients outcome globally

Addressing the risk of:

Aneurysmal subarachnoid hemorrhage

An Aneurysmal subarachnoid hemorrhage (aSAH) is an acute brain bleed caused by the rupture of a cerebral aneurysm – often in previously healthy individuals.

Reducing the risk of:

Delayed cerebral ischemia

In the critical phase delayed cerebral ischemia can drastically reduce blood flow to the brain, often resulting in severe neurological deficits or death.

New treatment methods:

Limited current treatment

Current treatment options are limited: Systemically administered drugs are often ineffective or cannot be used safely due to significant side effects.

54Ø

Patients average age

600K

Patients per year

50%

Patients with inadequate care

• Our Competence

Science translated into healing.

Born from clinical experience – advanced through research and technology. A team with more than 25 years of expertise in translational medicine and biosciences, complemented by strong process know-how, operational excellence, and entrepreneurial vision. Built on international reputation, global experience, and a network that connects research, clinical practice and industry.

Prof. Dr. Daniel Hänggi

CEO, Founder

Internationally recognized leader in neurosurgery and neuroscience; Director of Translational Neurosurgery, International Neuroscience Institute Hannover, Germany; Early leadership team member and Principal Investigator of a landmark first-in-human study Edge Therapeutics (NASDAQ IPO 2015)

Robert Schovenberg

CBO, Co-Founder

Entrepreneurial expertise from a serial founder and investor with a track record in building and scaling tech companies.

Dr. Christian Aichinger

COO, Co-Founder

Pharmaceutical market launch expertise from a manager with decades of experience in the development, launch and execution of therapies and medical devices in leading global companies.

Toru Takama

CEO TCT Japan

A entrepreneur and technologist who has spent four decades turning bold ideas into global realities — from co-developing with Apple and investing in US mobile and internet ventures, to serving as CTO and CEO within NTT Group. Now at TCT, he channels that same restless curiosity into drug delivery — asking what becomes possible when the innovation playbook from the world’s most dynamic industries is brought, for the first time, to getting the right treatment to exactly the right place.

Dr. Dirk Besse

Chairman of the Advisory Board

Dr. Dirk Besse is Managing Partner of the German office of Morrison Foerster and leads its European M&A practice. He specializes in cross-border transactions and capital markets law, focusing on pharma, finance, software, and high-tech. He has published widely and served on supervisory boards.

Dr. Timm Hassemer

Senior Project Manager

Cara Ludermann

Founders Associate

Miyuki Matsumoto

Founders Associate

Dr. Giulia Moscatiello

Manager Scientific Affairs

Yu Nakanishi

Founders Associate TCT Japan

Julia Wolfrat

Expert Advisor Quality Management

Nils Beyer

Expert Advisor in Regulatory Affairs

Steffen Gerbus

Expert Advisor in Taxation

Cornel Schnietz

Expert Advisor Data & Technology

Entrepreneurial and technological judgement from a co-founder and former CTO with more than 25 years of experience building, scaling and assessing software-driven businesses. Cornel co-founded CM4all / we22, whose cloud-based web presence products are used by hosting and telecommunications providers around the world. At TCT, he applies this experience to data- and AI-driven innovation strategy — helping translate complex scientific, technological and business possibilities into sharper hypotheses, better decisions and scalable structures.

• Shared Vision

Science United by a Shared Vision for New Medical Technologies

Progress in medicine rarely happens alone.
By bringing together researchers, clinicians, and technology experts, new medical solutions can be developed faster and translated into real therapies for patients worldwide.

Germany

India

Italy

Japan

Be part of our network

• Our Core Values